Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
4.360
-0.160 (-3.54%)
At close: Jul 11, 2025, 4:00 PM
4.390
+0.030 (0.69%)
After-hours: Jul 11, 2025, 6:27 PM EDT

Y-mAbs Therapeutics Revenue

Y-mAbs Therapeutics had revenue of $20.90M in the quarter ending March 31, 2025, with 4.88% growth. This brings the company's revenue in the last twelve months to $88.66M, up 4.92% year-over-year. In the year 2024, Y-mAbs Therapeutics had annual revenue of $87.69M with 3.38% growth.

Revenue (ttm)
$88.66M
Revenue Growth
+4.92%
P/S Ratio
2.20
Revenue / Employee
$852,481
Employees
104
Market Cap
197.49M

Revenue Chart

Revenue History

Fiscal Year End Revenue Change Growth
Dec 31, 2024 87.69M 2.87M 3.38%
Dec 31, 2023 84.82M 19.55M 29.96%
Dec 31, 2022 65.27M 30.37M 87.03%
Dec 31, 2021 34.90M 14.15M 68.18%
Dec 31, 2020 20.75M - -
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 410.06B
Johnson & Johnson 89.33B
Merck & Co. 63.92B
AbbVie 57.37B
AstraZeneca 54.98B
Novartis AG 53.22B
Eli Lilly and Company 49.00B
Novo Nordisk 43.92B
Revenue Rankings